Australia's most trusted
source of pharma news
Posted 20 January 2026 AM
The "greatest recalibration of patent law in Australia since the turn of the century" is being appealed to the High Court, and if the appeal fails many products will suddenly be open to legitimate generic competition.
On 1 December last year, the Full Federal Court ruled the patent term extension for Otsuka's Abilify Maintena had been wrongly granted, upholding the ruling of the Federal Court but changing the reason and in the process affecting a vast swath of other products.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.